Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 12.01.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | mpany’s related Annual Report on Form 10-K. Item 5.02 Departure of Directors or Certain Officers; Election of Director |
| 03.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 14.05.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 16.08.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain O |
| 08.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | by specific reference in such a filing. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; A |
| 13.03.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ge Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain |
| 21.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | by specific reference in such a filing. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; A |
| 13.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | forth by specific reference in such a filing. Item 5.02 Departure of Directors of Certain Officers; Election of Director |
Stammdaten
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Unternehmen & Branche
| Name | Outset Medical, Inc. |
|---|---|
| Ticker | OM |
| CIK | 0001484612 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Devices |
| SIC | 3845 · Electromedical & Electrotherapeutic Apparatus |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 78,3 Mio. USD |
| Beta | 1,96 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 119,476,000 | -81,653,000 | -5.37 | 264,496,000 | 126,952,000 |
| 2025-09-30 | 10-Q | 29,431,000 | -17,838,000 | -1.00 | 277,255,000 | 142,365,000 |
| 2025-06-30 | 10-Q | 31,419,000 | -18,541,000 | -1.04 | 288,801,000 | 154,784,000 |
| 2025-03-31 | 10-Q | 29,752,000 | -25,783,000 | -3.66 | 301,211,000 | 169,868,000 |
| 2024-12-31 | 10-K | 113,689,000 | -127,976,000 | -36.96 | 275,795,000 | 26,819,000 |
| 2024-09-30 | 10-Q | 28,666,000 | -27,940,000 | -8.02 | 292,890,000 | 47,822,000 |
| 2024-06-30 | 10-Q | 27,388,000 | -34,454,000 | -9.96 | 314,534,000 | 68,599,000 |
| 2024-03-31 | 10-Q | 28,168,000 | -39,944,000 | -11.77 | 346,242,000 | 93,200,000 |
| 2023-12-31 | 10-K | 130,376,000 | -172,797,000 | -52.28 | 313,801,000 | 122,886,000 |
| 2023-09-30 | 10-Q | 30,362,000 | -46,180,000 | -0.93 | 307,551,000 | 152,063,000 |
| 2023-06-30 | 10-Q | 36,040,000 | -44,046,000 | -0.90 | 334,442,000 | 183,108,000 |
| 2023-03-31 | 10-Q | 33,467,000 | -43,971,000 | -0.90 | 362,665,000 | 216,286,000 |
| 2022-12-31 | 10-K | 115,375,000 | -162,956,000 | -3.38 | 400,115,000 | 245,990,000 |
| 2022-09-30 | 10-Q | 27,761,000 | -40,781,000 | -0.85 | 365,722,000 | 279,103,000 |
| 2022-06-30 | 10-Q | 25,057,000 | -43,839,000 | -0.92 | 401,236,000 | 309,764,000 |
| 2022-03-31 | 10-Q | 30,550,000 | -36,892,000 | -0.78 | 431,742,000 | 345,453,000 |
| 2021-12-31 | 10-K | 102,602,000 | -131,935,000 | -2.89 | 463,464,000 | 374,081,000 |
| 2021-09-30 | 10-Q | 26,318,000 | -30,470,000 | -0.65 | 488,804,000 | 409,751,000 |
| 2021-06-30 | 10-Q | 25,216,000 | -30,208,000 | -0.66 | 504,813,000 | 431,162,000 |
| 2021-03-31 | 10-Q | 22,916,000 | -30,025,000 | -0.70 | 379,829,000 | 306,645,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-02-17 | Brottem John L. | Officer, General Counsel | Open Market Sale | -2,842 | 3.35 | -9,520.70 | -82,6% | |
| 2026-02-17 | Trigg Leslie | Director, Officer, Chair and CEO | Open Market Sale | -3,361 | 3.35 | -11,259.35 | -97,6% | |
| 2026-02-17 | Nash Marc | Officer, EVP Operations R&D & Service | Open Market Sale | -1,817 | 3.35 | -6,086.95 | -52,8% | |
| 2026-01-21 | Nash Marc | Officer, EVP Operations R&D & Service | Open Market Sale | -980 | 4.98 | -4,880.40 | -42,3% | |
| 2026-01-21 | Trigg Leslie | Director, Officer, Chair and CEO | Open Market Sale | -2,120 | 5.05 | -10,706.00 | -92,8% | |
| 2026-01-21 | Brottem John L. | Officer, General Counsel | Open Market Sale | -1,180 | 5.01 | -5,911.80 | -51,3% | |
| 2026-01-20 | Nash Marc | Officer, EVP Operations R&D & Service | Open Market Sale | -5,375 | 5.12 | -27,520.00 | -238,6% | |
| 2026-01-20 | Brottem John L. | Officer, General Counsel | Open Market Sale | -9,314 | 5.12 | -47,687.68 | -413,5% | |
| 2026-01-20 | Trigg Leslie | Director, Officer, Chair and CEO | Open Market Sale | -11,794 | 5.12 | -60,385.28 | -523,6% | |
| 2026-01-07 | Nash Marc | Officer, EVP Operations R&D & Service | Open Market Sale | -108 | 4.27 | -461.16 | -4,0% | |
| 2026-01-07 | Brottem John L. | Officer, General Counsel | Open Market Sale | -224 | 4.27 | -956.48 | -8,3% | |
| 2026-01-07 | Trigg Leslie | Director, Officer, Chair and CEO | Open Market Sale | -1,795 | 4.27 | -7,664.65 | -66,5% | |
| 2025-12-01 | Drexler Karen | Director | Open Market Sale | -1,548 | 4.37 | -6,764.76 | -58,7% | |
| 2025-11-17 | Trigg Leslie | Director, Officer, Chair and CEO | Open Market Sale | -916 | 4.60 | -4,213.60 | -36,5% | |
| 2025-11-17 | Brottem John L. | Officer, General Counsel | Open Market Sale | -388 | 4.60 | -1,784.80 | -15,5% | |
| 2025-11-17 | Nash Marc | Officer, EVP Operations R&D & Service | Open Market Sale | -247 | 4.60 | -1,136.20 | -9,9% | |
| 2025-08-15 | Brottem John L. | Officer, General Counsel | Open Market Sale | -383 | 12.88 | -4,933.04 | -42,8% | |
| 2025-08-15 | Trigg Leslie | Director, Officer, Chair and CEO | Open Market Sale | -904 | 12.88 | -11,643.52 | -101,0% | |
| 2025-08-15 | Nash Marc | Officer, SVP Operations and R&D | Open Market Sale | -243 | 12.88 | -3,129.84 | -27,1% | |
| 2025-05-15 | Nash Marc | Officer, SVP Operations and R&D | Open Market Sale | -252 | 17.82 | -4,490.64 | -38,9% | |
| 2025-05-15 | Brottem John L. | Officer, General Counsel | Open Market Sale | -396 | 17.82 | -7,056.72 | -61,2% | |
| 2025-05-15 | Trigg Leslie | Director, Officer, Chair and CEO | Open Market Sale | -935 | 17.80 | -16,643.00 | -144,3% | |
| 2025-05-15 | Ahmed Nabeel | Officer, Chief Financial Officer | Open Market Sale | -584 | 17.81 | -10,401.04 | -90,2% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.